Antiemetic Efficacy of High-Dose Dexamethasone in Induction Therapy in Acute Nonlymphocytic Leukemia
Authors: Peter A. Cassileth, Edward J. Lusk, Susan Torri, Stanton L. Gerson
Journal: Annals of Internal Medicine (1984)

Brief Reports1 May 1984Antiemetic Efficacy of High-Dose Dexamethasone in Induction Therapy in Acute Nonlymphocytic LeukemiaPETER A. CASSILETH, M.D., EDWARD J. LUSK, Ph.D., SUSAN TORRI, R.N., STANTON L. GERSON, M.D.PETER A. CASSILETH, M.D.Search for more papers by this author, EDWARD J. LUSK, Ph.D.Search for more papers by this author, SUSAN TORRI, R.N.Search for more papers by this author, STANTON L. GERSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-5-701 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNausea and vomiting continue to be distressing side effects of cancer chemotherapy. We recently reported (1) a randomized, double-blind study in which a single 10-mg dose of intravenous dexamethasone markedly reduced the gastrointestinal side effects of mildly emetogenic chemotherapy for outpatients with breast cancer. We now report the safety and efficacy of repeated doses of dexamethasone in eliminating the nausea and vomiting of induction chemotherapy for patients with acute nonlymphocytic leukemia.All patients included in the study were adults with acute nonlymphocytic leukemia (at diagnosis or on relapse) at the Hospital of the University of Pennsylvania and were treated with...References1. CASSILETHLUSKTORRIDINUBILEGERSON PESNS. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med. 1983;143:1347-9. CrossrefMedlineGoogle Scholar2. SEIGELLONGO LD. The control of chemotherapy-induced emesis. Ann Intern Med. 1981;95:352-9. LinkGoogle Scholar3. GRALLAITRIPISKO RLS. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305:905-9. CrossrefMedlineGoogle Scholar4. SALLANCRONINZELENZINBERG SCMN. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302:135-8. CrossrefMedlineGoogle Scholar5. MEYERLONGNATALEKOLLERMIODUSZEWSKI MARCJ. Phase I, II and III trials of a new antiemetic agent—lorazepam [Abstract]. Proc Am Soc Clin Oncol. 1983;2:88. Google Scholar6. GRUNBERGGALALAMPENFELD SKM. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and highdose intravenous haldol in a randomized double-blind crossover study [Abstract]. Proc Am Soc Clin Oncol. 1983;2:85. Google Scholar7. FRUSTACITUMOLOTIRELLI SSU. High dose metoclopramide versus dexamethasone in the prevention of cis-platinum induced vomiting: a cross-over randomized study [Abstract]. Proc Am Soc Clin Oncol. 1983;2:87. Google Scholar8. MCDERMED J. A randomized, cross-over comparison of the effectiveness of intravenous metoclopramide and IV dexamethasone as antiemetic prevention in cancer chemotherapy [Abstract]. Proc Am Soc Clin Oncol. 1983;2:88. Google Scholar9. AAPROPLEZIA MP. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide [Abstract]. Proc Am Soc Clin Oncol. 1983;2:93. Google Scholar10. ARTIMDIBELLA RN. Tetrahydrocannabinol plus prochlorperazine for refractory nausea and vomiting [Abstract]. Proc Am Soc Clin Oncol. 1983;2:85. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByNausea and VomitingEnhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug deliveryNausea and VomitingSymptom Management in Children with CancerNausea and VomitingSurvey of Serotonin Receptor Antagonist Usage at National Cancer Center HospitalGastrointestinal Toxicity of Chemotherapeutic AgentsRecommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesSynthesis, structure, and antitumor activity of 1,3-dithiol- and 1,3-dithiolan-2-ylidenemalonatoplatinum(II) complexesControl of Chemotherapy-Induced EmesisNausea and VomitingAdvances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimensToxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomesThe pharmacokinetics of single high doses of dexamethasone in cancer patientsDEXAMETHASONE ANTIEMESIS AND SIDE-EFFECTSAntiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapyDexamethasone-Induced Perineal IrritationComparison of Metoclopramide and Metoclopramide Plus Dexamethasone for Complete Protection from Cisplatinum-Induced EmesisThe synthesis and antitumor properties of a series of water soluble carboxylato-( 1,2-diaminocyclohexane) platinum(II) complexesControl of cancer chemotherapy-induced nausea and vomitingDexamethasone as an Antiemetic During Cancer ChemotherapyHANS W. GRUNWALD, M.D., FRED ROSNER, M.D.Risks in Antiemesis Using DexamethasoneMAY M. ALHASHIMI, M.D., STEVEN H. KRASNOW, M.D., ANITA JOHNSTON-EARLY, R.N., MARC L. CITRON, M.D., MARTIN H. COHEN, M.D. 1 May 1984Volume 100, Issue 5Page: 701-702KeywordsAcute myeloid leukemiaBreast cancerCancer chemotherapyChemotherapyHematology and oncologyNauseaOutpatientsSafetyVomiting Issue Published: 1 May 1984 PDF DownloadLoading ...